問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Urology

Division of Thoracic Medicine

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Hematology & Oncology

National Taiwan University Cancer Center (在職)

Division of Hematology & Oncology

Division of Hematology & Oncology

更新時間：2025-09-17

林家齊Lin, Chia-Chi
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

372Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林家齊

List

681Cases

2023-04-01 - 2025-12-31

Phase I/II

Active
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1)

  • Condition/Disease

    Locally Advanced Solid Tumor、 Metastatic Solid Tumor

  • Test Drug

    膜衣錠

Participate Sites
3Sites

Recruiting3Sites

2023-12-01 - 2027-12-31

Phase I

Completed
A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    MYTX-011

Participate Sites
6Sites

Recruiting6Sites

2022-05-01 - 2024-08-16

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-10-01 - 2024-07-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-04-18 - 2023-05-16

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting2Sites

Terminated1Sites

2019-06-01 - 2023-11-16

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2022-06-17 - 2022-06-17

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2023-02-23 - 2026-10-31

Phase I

Active
A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)

  • Condition/Disease

    Locally Advanced Solid Tumor、 Metastatic Solid Tumor

  • Test Drug

    NVL-520

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

2023-03-01 - 2026-10-30

Phase I

Active
A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer

  • Condition/Disease

    HER2 Mutant Non-small Cell Lung Cancer

  • Test Drug

    膠囊劑 注射劑 注射劑

Participate Sites
5Sites

Recruiting5Sites

2023-05-01 - 2025-12-31

Phase I

Active
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors

  • Condition/Disease

    Solid Tumor

  • Test Drug

    錠劑 注射用凍晶粉末

Participate Sites
2Sites

Recruiting2Sites

1 2 3 4 5 69
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB